MKK4 is a negative regulator of the TGF-β1 (transforming growth factor-β1) signaling pathway associated with remodeling and arrhythmogenesis with age, and has been suggested as a potential therapeutic target for the treatment of atrial fibrillation [130]. This evidence concerns the gene MAP2K4 and atrial fibrillation.